Zhengye Biotechnology (ZYBT) Competitors

$0.87 -0.05 (-5.74%)

Closing price 04:00 PM Eastern

Extended Trading

$0.87 +0.00 (+0.11%)

As of 04:04 PM Eastern

ZYBT vs. ENLV, HRTX, PRQR, IFRX, and DERM

Should you buy Zhengye Biotechnology stock or one of its competitors? MarketBeat compares Zhengye Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zhengye Biotechnology include Enlivex Therapeutics (ENLV), Heron Therapeutics (HRTX), ProQR Therapeutics (PRQR), InflaRx (IFRX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry.

How does Zhengye Biotechnology compare to Enlivex Therapeutics?

Zhengye Biotechnology (NASDAQ:ZYBT) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Enlivex Therapeutics' return on equity of 248.08% beat Zhengye Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Enlivex Therapeutics	N/A	248.08%	206.39%

Enlivex Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 2,242.09%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enlivex Therapeutics has lower revenue, but higher earnings than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A

1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zhengye Biotechnology has a beta of -2.47, suggesting that its share price is 347% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

In the previous week, Enlivex Therapeutics had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Enlivex Therapeutics and 0 mentions for Zhengye Biotechnology. Enlivex Therapeutics' average media sentiment score of 0.25 beat Zhengye Biotechnology's score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Enlivex Therapeutics	Neutral

Summary

Enlivex Therapeutics beats Zhengye Biotechnology on 11 of the 12 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

In the previous week, Heron Therapeutics had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Heron Therapeutics and 0 mentions for Zhengye Biotechnology. Heron Therapeutics' average media sentiment score of 0.01 beat Zhengye Biotechnology's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Neutral
Zhengye Biotechnology	Neutral

80.0% of Heron Therapeutics shares are held by institutional investors. 5.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Zhengye Biotechnology has lower revenue, but higher earnings than Heron Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$150.71M	1.07	-$20.19M	-$0.18	N/A
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A

Zhengye Biotechnology has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Zhengye Biotechnology's return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
Zhengye Biotechnology	N/A	N/A	N/A

Heron Therapeutics has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, indicating that its share price is 347% less volatile than the broader market.

Heron Therapeutics presently has a consensus target price of $4.50, indicating a potential upside of 430.60%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Heron Therapeutics beats Zhengye Biotechnology on 10 of the 14 factors compared between the two stocks.

How does Zhengye Biotechnology compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Zhengye Biotechnology has higher revenue and earnings than ProQR Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	8.37	-$47.73M	-$0.50	N/A
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A

In the previous week, ProQR Therapeutics had 4 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 4 mentions for ProQR Therapeutics and 0 mentions for Zhengye Biotechnology. ProQR Therapeutics' average media sentiment score of 0.30 beat Zhengye Biotechnology's score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
ProQR Therapeutics	Neutral
Zhengye Biotechnology	Neutral

32.7% of ProQR Therapeutics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zhengye Biotechnology has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Zhengye Biotechnology's return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Zhengye Biotechnology	N/A	N/A	N/A

ProQR Therapeutics currently has a consensus price target of $7.25, indicating a potential upside of 406.99%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe ProQR Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ProQR Therapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, indicating that its share price is 347% less volatile than the broader market.

Summary

ProQR Therapeutics beats Zhengye Biotechnology on 9 of the 14 factors compared between the two stocks.

How does Zhengye Biotechnology compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Zhengye Biotechnology's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
Zhengye Biotechnology	N/A	N/A	N/A

42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Zhengye Biotechnology has higher revenue and earnings than InflaRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	5,710.91	-$51.63M	-$0.71	N/A
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A

In the previous week, InflaRx had 5 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 5 mentions for InflaRx and 0 mentions for Zhengye Biotechnology. InflaRx's average media sentiment score of 0.53 beat Zhengye Biotechnology's score of 0.00 indicating that InflaRx is being referred to more favorably in the media.

Company	Overall Sentiment
InflaRx	Positive
Zhengye Biotechnology	Neutral

InflaRx presently has a consensus target price of $7.00, indicating a potential upside of 195.36%. Given InflaRx's stronger consensus rating and higher possible upside, equities research analysts plainly believe InflaRx is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InflaRx has a beta of 2.42, indicating that its stock price is 142% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, indicating that its stock price is 347% less volatile than the broader market.

Summary

InflaRx beats Zhengye Biotechnology on 10 of the 14 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Zhengye Biotechnology has higher revenue and earnings than Journey Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.72	-$11.43M	-$0.37	N/A
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A

In the previous week, Journey Medical had 20 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 20 mentions for Journey Medical and 0 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.00 beat Journey Medical's score of -0.51 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Journey Medical	Negative
Zhengye Biotechnology	Neutral

Zhengye Biotechnology has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Zhengye Biotechnology's return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
Zhengye Biotechnology	N/A	N/A	N/A

Journey Medical has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, indicating that its stock price is 347% less volatile than the broader market.

Journey Medical currently has a consensus price target of $13.00, indicating a potential upside of 111.38%. Given Journey Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Journey Medical is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.3% of Journey Medical shares are owned by institutional investors. 15.0% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Journey Medical beats Zhengye Biotechnology on 8 of the 14 factors compared between the two stocks.

Get Zhengye Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYBT vs. The Competition

Export

Metric	Zhengye Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$41.23M	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	N/A	18.70	20.60	25.11
Price / Sales	0.35	278.20	577.42	91.29
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	0.94	6.57	9.68	6.60
Net Income	-$9.98M	$24.30M	$3.55B	$335.60M
7 Day Performance	-13.86%	-3.56%	-2.07%	-2.03%
1 Month Performance	-12.17%	-7.86%	-3.90%	-1.90%
1 Year Performance	-90.37%	51.80%	29.37%	27.35%

Zhengye Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYBT Zhengye Biotechnology	N/A	$0.87 -5.7%	N/A	-88.2%	$41.23M	$116.36M	N/A	278	Short Interest Decrease
ENLV Enlivex Therapeutics	2.38 of 5 stars	$0.74 +0.6%	$16.50 +2,138.8%	-30.3%	$174.95M	N/A	N/A	70	News Coverage
HRTX Heron Therapeutics	2.2281 of 5 stars	$0.92 +0.3%	$4.50 +390.7%	-56.4%	$173.57M	$154.90M	N/A	300	Analyst Downgrade
PRQR ProQR Therapeutics	3.4112 of 5 stars	$1.65 -3.2%	$7.25 +340.7%	-6.8%	$173.32M	$15.91M	N/A	180	Earnings Report Analyst Downgrade
IFRX InflaRx	3.5445 of 5 stars	$2.40 -5.0%	$7.00 +192.3%	+50.6%	$173.14M	$29.33K	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYBT) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. ENLV, HRTX, PRQR, IFRX, and DERM

How does Zhengye Biotechnology compare to Enlivex Therapeutics?

Summary

How does Zhengye Biotechnology compare to Heron Therapeutics?

Summary

How does Zhengye Biotechnology compare to ProQR Therapeutics?

Summary

How does Zhengye Biotechnology compare to InflaRx?

Summary

How does Zhengye Biotechnology compare to Journey Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. ENLV, HRTX, PRQR, IFRX, and DERM

How does Zhengye Biotechnology compare to Enlivex Therapeutics?

Is ZYBT or ENLV more profitable?

Do analysts prefer ZYBT or ENLV?

Which has stronger earnings & valuation, ZYBT or ENLV?

Do institutionals and insiders have more ownership in ZYBT or ENLV?

Which has more risk & volatility, ZYBT or ENLV?

Does the media favor ZYBT or ENLV?

Summary

How does Zhengye Biotechnology compare to Heron Therapeutics?

Does the media refer more to HRTX or ZYBT?

Do insiders and institutionals hold more shares of HRTX or ZYBT?

Which has higher earnings and valuation, HRTX or ZYBT?

Is HRTX or ZYBT more profitable?

Which has more volatility & risk, HRTX or ZYBT?

Do analysts prefer HRTX or ZYBT?

Summary

How does Zhengye Biotechnology compare to ProQR Therapeutics?

Which has preferable valuation and earnings, PRQR or ZYBT?

Does the media prefer PRQR or ZYBT?

Do insiders & institutionals hold more shares of PRQR or ZYBT?

Is PRQR or ZYBT more profitable?

Do analysts prefer PRQR or ZYBT?

Which has more volatility and risk, PRQR or ZYBT?

Summary

How does Zhengye Biotechnology compare to InflaRx?

Is IFRX or ZYBT more profitable?

Do institutionals and insiders hold more shares of IFRX or ZYBT?

Which has better earnings & valuation, IFRX or ZYBT?

Does the media prefer IFRX or ZYBT?

Do analysts prefer IFRX or ZYBT?

Which has more risk & volatility, IFRX or ZYBT?

Summary

How does Zhengye Biotechnology compare to Journey Medical?

Which has higher valuation & earnings, DERM or ZYBT?

Does the media prefer DERM or ZYBT?

Is DERM or ZYBT more profitable?

Which has more risk and volatility, DERM or ZYBT?

Do analysts prefer DERM or ZYBT?

Do institutionals & insiders hold more shares of DERM or ZYBT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools